MA55557A - Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations - Google Patents

Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations

Info

Publication number
MA55557A
MA55557A MA055557A MA55557A MA55557A MA 55557 A MA55557 A MA 55557A MA 055557 A MA055557 A MA 055557A MA 55557 A MA55557 A MA 55557A MA 55557 A MA55557 A MA 55557A
Authority
MA
Morocco
Prior art keywords
orally administered
solid forms
lactamase inhibitor
administered beta
beta
Prior art date
Application number
MA055557A
Other languages
English (en)
Inventor
Steven A Boyd
Christopher J Burns
Stephen M Condon
Yijun Deng
Eugen F Mesaros
Lawrence Rosen
Robert Simpson
Robert E Lee Trout
Allison L Zulli
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of MA55557A publication Critical patent/MA55557A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055557A 2019-04-02 2020-04-01 Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations MA55557A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962828349P 2019-04-02 2019-04-02

Publications (1)

Publication Number Publication Date
MA55557A true MA55557A (fr) 2022-02-09

Family

ID=72666564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055557A MA55557A (fr) 2019-04-02 2020-04-01 Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations

Country Status (14)

Country Link
US (1) US20220194964A1 (fr)
EP (1) EP3946364A4 (fr)
JP (1) JP2022529212A (fr)
KR (1) KR20210146979A (fr)
CN (1) CN113905741A (fr)
AU (1) AU2020256179A1 (fr)
BR (1) BR112021019656A2 (fr)
CA (1) CA3135614A1 (fr)
EA (1) EA202192669A1 (fr)
IL (1) IL286850A (fr)
MA (1) MA55557A (fr)
SG (1) SG11202110683WA (fr)
TW (1) TW202102230A (fr)
WO (1) WO2020205932A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (fr) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de protéines de liaison à la pénicilline
SG11202105505TA (en) * 2018-11-29 2021-06-29 Venatorx Pharmaceuticals Inc Combination compositions comprising a beta-lactamase inhibitor and uses thereof
KR20230062075A (ko) 2021-10-29 2023-05-09 코웨이 주식회사 제빙용 증발기

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
US9422314B2 (en) * 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RU2686740C2 (ru) * 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
WO2017100537A1 (fr) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
SG11202105505TA (en) * 2018-11-29 2021-06-29 Venatorx Pharmaceuticals Inc Combination compositions comprising a beta-lactamase inhibitor and uses thereof

Also Published As

Publication number Publication date
EA202192669A1 (ru) 2022-03-01
JP2022529212A (ja) 2022-06-20
EP3946364A1 (fr) 2022-02-09
BR112021019656A2 (pt) 2022-01-18
KR20210146979A (ko) 2021-12-06
AU2020256179A1 (en) 2021-11-18
EP3946364A4 (fr) 2023-01-18
CA3135614A1 (fr) 2020-10-08
IL286850A (en) 2021-10-31
WO2020205932A1 (fr) 2020-10-08
CN113905741A (zh) 2022-01-07
TW202102230A (zh) 2021-01-16
SG11202110683WA (en) 2021-10-28
US20220194964A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
MA55557A (fr) Formes solides d'un inhibiteur de bêta-lactamases administré par voie orale et leurs utilisations
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
CL2018002924A1 (es) Inhibidores de bromodominios
MA51848A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52765A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA47743A (fr) Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
MA48779A (fr) Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
MA54947A (fr) Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
MA53381A (fr) Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
MA47301B1 (fr) Inhibiteurs sélectifs de jak1
MA56226A (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
MA54051A (fr) Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations
MA54544A (fr) Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale
MA42509A (fr) Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton
MA55015A (fr) Formulations pharmaceutiques
MA52021A (fr) Anticorps anti-lif et leurs formes galéniques
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
MA54222A (fr) Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées
EA202190077A1 (ru) Ингибиторы гистондеацетилазы
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
MA53099A (fr) Formes d'ivosidénib et compositions pharmaceutiques
MX2019004375A (es) Inhibidores de bromodominios.
MA52485A (fr) Combinaisons de variants d'anticorps et utilisations associées